Searchable abstracts of presentations at key conferences in endocrinology

ea0081ap4 | Clinical Endocrinology Trust Award Lecture | ECE2022

Setting the scene for (rare) endocrine diseases in Europe

Pereira Alberto M

My research focuses on the long-term consequences of pituitary diseases, and on the effects of stress hormones on the central nervous system (CNS) in specific. This has elucidated long-term effects of hormone excess on the CNS, as well as on other organs that affect stress-resilience, and consequently, general well-being and quality of life. This profoundly affects our understanding of the biological effects of stress hormone excess on the CNS, and on the care for patients wit...

ea0070ep295 | Pituitary and Neuroendocrinology | ECE2020

Pre-operative full blood count, C-reactive protein and serum inflammation-based scores may predict aggressive or refractory disease in patients with pituitary adenomas

Marques Pedro , de Vries Friso , van Furth Wouter , Korbonits Marta , Biermasz Nienke , Pereira Alberto M

Introduction: Full blood count (FBC), C-reactive protein (CRP), albumin and serum inflammation-based scores reflect systemic inflammation and predict outcomes in oncological patients. While these are increasingly used in cancer, little is known in pituitary adenomas (PAs). We aimed to characterise FBC and inflammation-based scores in patients with PAs and investigate the usefulness of such parameters in predicting aggressive/refractory disease.Methods: W...

ea0081ep154 | Calcium and Bone | ECE2022

Clinical outcomes of COVID-19 infection in rare bone and mineral disorders

Zurita Ana Luisa Priego , Bryce Jillian , Brandi Maria-Luisa , Glasberg Simona , Pereira Alberto M , Sangiorgi Luca , Schalin-Jantti Camilla , van den Akker Erica , Ahmed Faisal , Appelman-Dijkstra Natasha

Background The European Registries for Rare Endocrine Conditions and the European Registries for Rare Bone and Mineral Conditions were created in collaboration with the European Reference Networks for Rare Endocrine and Bone Disorders (Endo-ERN and ERN BOND). Following the onset of the COVID-19 pandemic in 2020, the registries, together with the ESE RD Committee, have collected the occurrence of confirmed and suspected cases of COVID-19 in patients with rare endocrine and bone...

ea0090oc5.6 | Oral Communications 5: Adrenal and Cardiovascular Endocrinology 1 | ECE2023

Venous thromboembolism complications in Cushing’s syndrome: results of a secondary survey within the European Registries for Rare Endocrine Conditions (EuRRECa) and the European Reference Network on Rare Endocrine Conditions (Endo-ERN)

Cherenko Mariya , Appelman-Dijkstra Natasha , Priego Zurita Ana Luisa , Klok F.A. , Biermasz Nienke , M. Dekkers Olaf , Ahmed Faisal , Pereira Alberto M.

Background: Venous thromboembolism(VTE) is a well-known perioperative complication in patients with Cushing’s syndrome(CS) and may be preventable. A recent report highlighted that thromboprophylaxis management in patients with CS still varies considerably across Endo-ERN reference centers but the actual incidence of VTE and its management in individual patients is unclear.Aim: To collect epidemiological and clinical data of new cases of CS reported ...

ea0070aep595 | Pituitary and Neuroendocrinology | ECE2020

Gallium-68 -DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas

M. Boertien Tessel , Booij Jan , Majoie Charles BLM , Drent ML , Pereira Alberto M , Biermasz Nienke , Simsek Suat , Groote Veldman Ronald , Stokkel Marcel PM , Bisschop Peter H , Fliers Eric

Background: Clinically non-functioning pituitary macroadenomas (NFMA) have been reported to express various somatostatin receptor (SSTR) subtypes, but results are inconsistent across different studies. This may be related to limited sensitivity and specificity of techniques used to date, i.e. immunohistochemistry in surgical specimens and 111In-DTPA-octreotide scintigraphy (Octreoscan) in vivo. The aim of this study was to assess SSTR expression in NFMA <em...

ea0070aep753 | Pituitary and Neuroendocrinology | ECE2020

SF-12 or SF-36 in pituitary disease? towards concise patient-reported outcomes measurements

Van der Meulen Merel , Biermasz Nienke , Zamanipoor Najafabadi Amir , Lobatto Daniel , van Furth Wouter , Andela Cornelie , Pereira Alberto M , Vliet-Vlieland Thea P.M.

Objective: Pituitary diseases cause a wide range of local and systemic symptoms and severely affect patients’ health-related quality of life (HRQoL), which can be monitored using both disease-specific and generic questionnaires. The most frequently used generic HRQoL questionnaire is the Short Form-36 (SF-36), generating a mental (MCS) and physical component score (PCS). The shorter 12-item version (SF-12) can improve efficiency of patient monitoring and outcome measurem...

ea0070aep1076 | Hot topics (including COVID-19) | ECE2020

Outcome squares integrating efficacy and safety, as applied to functioning pituitary adenoma surgery

de Vries Friso , Lobatto Daniel , Verstegen Marco , Schutte Pieter , Notting Irene , Kruit Mark , Ahmed Fasial , Pereira Alberto M , van Furth Wouter , Biermasz Nienke

Background: Transsphenoidal surgery is standard care in the treatment of hormone-secreting pituitary adenomas. Current clinician-reported surgical outcome measures are one-dimensional, typically focussing primarily on complete or partial resection and secondarily on complication rates. However, outcomes are best reflected by the delicate balance of efficacy and complications at patient level. This study proposes a novel way to classify outcome, integrating efficacy and safety ...

ea0020p545 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Pre-treatment IGF-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease

Biermasz Nienke R , Wassenaar Moniek J E , van der Klaauw Agatha A , Pereira Alberto M , Smit Johannes W A , Roelfsema Ferdinand , Wolterbeek Ron , Kroon Herman M , Kloppenburg Margreet , Romijn Johannes A

Objective: To identify factors influencing the development of osteoarthritis during long-term control of acromegaly, focusing on disease specific parameters, growth hormone (GH) and insulin-like growth factor I (IGF-I) concentrations and duration of disease, adjusted for the well-known determinants of primary osteoarthritis.Design: Follow-up study.Methods: We studied 67 patients, with adequate biochemical control of acromegaly for ...

ea0056gp202 | Pituitary Clinical | ECE2018

Endoscopic vs microscopic transsphenoidal surgery for Cushing’s disease: a systematic review and meta-analysis

Broersen Leonie H A , Biermasz Nienke R , van Furth Wouter R , de Vries Friso , Verstegen Marco J T , Dekkers Olaf M , Pereira Alberto M

Background: Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, resulting in glucocorticoid excess. First-choice treatment is transsphenoidal pituitary surgery, using either a microscopic or endoscopic technique. Convincing evidence supporting the choice for one of both techniques, either based on treatment results or complication rate, is lacking.Objective: We aimed to compare endoscopic and microscopic...

ea0073oc6.3 | Oral Communications 6: Calcium and Bone | ECE2021

Bone material strength index is altered in patients with Cushing’s syndrome even after long-term remission

Schoeb Manuela , Sintenie Paula J.C. , Haalen Femke van , Nijhoff Michiel , de Vries Friso , Biermasz Nienke , Winter Elizabeth M. , Pereira Alberto M , Appelman-Dijkstra Natasha

BackgroundEndogenous Cushing’s syndrome (CS) is detrimental to bone. The skeletal complications are characterized by decreased bone formation and increased bone resorption, resulting in decreased bone mineral density (BMD) and an increased risk of fractures at time of diagnosis. After remission of the disease, BMD improves towards normal values but fracture rate remains elevated. Therefore, components of bone quality other than BMD, such as bone mat...